



MAPLE-BROWN ABBOTT

INVESTMENT MANAGERS SINCE 1984

15 March 2024

Maple-Brown Abbott funds BPAY® payment limit update

Maple-Brown Abbott Limited ABN 73 001 208 564 AFSL 237296 (MBA) as responsible entity of the Maple-Brown Abbott Funds set out in Table 1 (collectively, the **MBA Funds** and individually, a **Fund**) has increased the payment limit for BPAY® payments to \$250,000.

The Additional Information Booklet (AIB) for the MBA Funds dated 31 January 2024 is updated in accordance with this document.

This update should be read together with the product disclosure statement of the relevant fund (PDS) and AIB available at maple-brownabbott.com/document-library/ or by calling 1300 097 995. Information in the PDS and AIB is subject to change and may be updated from time to time. *ASIC Corporations (Updated Product Disclosure Statements) Instrument 2016/1055* permits such update to be made via the MBA website where the change is not materially adverse.

Effective 15 March 2024, the AIB is updated as follows:

1. The AIB is updated to replace 'A payment limit of \$99,999 applies' with 'A payment limit of \$250,000 applies'.

Table 1

Maple-Brown Abbott Fund	ARSN
Maple-Brown Abbott Asian Investment Trust	102 593 457
Maple-Brown Abbott Australian Equity Trust	091 136 266
Maple-Brown Abbott Australian Share Fund - Wholesale	087 294 504
Maple-Brown Abbott Australian Small Companies Fund	658 552 688
Maple-Brown Abbott Australian Sustainable Future Fund	616 876 263
Maple-Brown Abbott Australian Value Opportunities Fund	091 138 233
Maple-Brown Abbott Diversified Investment Trust	091 137 638
Maple-Brown Abbott Global Emerging Markets Equity Fund	657 440 894
Maple-Brown Abbott Global Listed Infrastructure Fund	164 901 982
Maple-Brown Abbott Global Listed Infrastructure Fund - Hedged	606 589 511

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. An investment in a Fund does not represent an investment in, deposit with or other liability of MBA, and is subject to investment risk including possible delays in repayment and loss of income and principal invested. Before making a decision whether to acquire, or to continue to hold an investment in a Fund, investors should obtain and consider the current Product Disclosure Statement, Additional Information Booklet and Target Market Determination (TMD) for the relevant Fund issued by MBA and available at maple-brownabbott.com/document-library/.



MAPLE-BROWN ABBOTT

INVESTMENT MANAGERS SINCE 1984

12 August 2024

Update to the Maple-Brown Abbott Diversified Investment Trust Product Disclosure Statement

Effective 7 August 2024 the disclosure relating to the strategic asset allocation of the Maple-Brown Abbott Diversified Investment Trust (ARSN 091 137 638) (**Fund**) set out in the following section of Fund's Product Disclosure Statement (**PDS**) dated 31 January 2024 has been updated.

1. the "Asset allocation ranges" row in the table in section 5 "How we invest your money":

Asset allocation ranges	Existing wording			Updated wording		
	Minimum %	Maximum %	Neutral %	Minimum %	Maximum %	Neutral %
Growth Assets	50	90	68	50	90	67
Australian equities	25	60	38	25	60	36
International equities	10	35	24	10	35	25
REITs	0	15	6	0	15	6
Defensive Assets	10	50	32	10	50	33
Fixed interest	10	50	18	10	50	19
Alternative assets	0	15	7	0	15	7
Cash	0	25	7	0	25	7
			100			100

This update should be read together with the PDS and AIB available at [maple-brownabbott.com/document-library/](https://www.maple-brownabbott.com/document-library/) or by calling 1300 097 995. Information in the PDS and AIB is subject to change and may be updated from time to time. *ASIC Corporations (Updated Product Disclosure Statements) Instrument 2016/1055* permits such update to be made via the Maple-Brown Abbott Limited website where the change is not materially adverse.

This document is prepared and issued by Maple-Brown Abbott Limited ABN 73 001 208 564, AFSL 237296 ("MBA"). This document contains general information only, and does not take into account your investment objectives, financial situation or specific needs. An investment in the Fund does not represent an investment in, deposit with or other liability of MBA, and is subject to investment risk including possible delays in repayment and loss of income and principal invested. Before making a decision whether to acquire, or to continue to hold an investment in the Fund, investors should obtain and consider the current Product Disclosure Statement, Additional Information Booklet and Target Market Determination for the Fund issued by MBA and available at [maple-brownabbott.com/document-library/](https://www.maple-brownabbott.com/document-library/).